Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker

Daniel Heinrich; Oyvind Bruland; Theresa A. Guise; Hiroyoshi Suzuki; Oliver Sartor

doi:10.2217/fon-2018-0087

Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker

Daniel Heinrich, Oyvind Bruland, Theresa A. Guise, Hiroyoshi Suzuki, Oliver Sartor

Research output: Contribution to journal › Review article › peer-review

47 Scopus citations

Abstract

Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

Original language	English (US)
Pages (from-to)	2543-2556
Number of pages	14
Journal	Future Oncology
Volume	14
Issue number	24
DOIs	https://doi.org/10.2217/fon-2018-0087
State	Published - Oct 2018

Keywords

Alkaline phosphatase
Biomarker
Bone metastases
Castration-resistant prostate cancer
Mechanism of action
Prognostic marker
Survival

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2018-0087

Cite this

@article{4f889386e98b48c78f89a7ecf073c122,

title = "Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker",

abstract = "Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.",

keywords = "Alkaline phosphatase, Biomarker, Bone metastases, Castration-resistant prostate cancer, Mechanism of action, Prognostic marker, Survival",

author = "Daniel Heinrich and Oyvind Bruland and Guise, {Theresa A.} and Hiroyoshi Suzuki and Oliver Sartor",

note = "Funding Information: The authors thank Heather Nyce of SciStrategy Communications for professional manuscript writing support, funded by Bayer HealthCare Pharmaceuticals. Publisher Copyright: {\textcopyright} 2018 authors.",

year = "2018",

month = oct,

doi = "10.2217/fon-2018-0087",

language = "English (US)",

volume = "14",

pages = "2543--2556",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "24",

}

TY - JOUR

T1 - Alkaline phosphatase in metastatic castration-resistant prostate cancer

T2 - Reassessment of an older biomarker

AU - Heinrich, Daniel

AU - Bruland, Oyvind

AU - Guise, Theresa A.

AU - Suzuki, Hiroyoshi

AU - Sartor, Oliver

N1 - Funding Information: The authors thank Heather Nyce of SciStrategy Communications for professional manuscript writing support, funded by Bayer HealthCare Pharmaceuticals. Publisher Copyright: © 2018 authors.

PY - 2018/10

Y1 - 2018/10

N2 - Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

AB - Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.

KW - Alkaline phosphatase

KW - Biomarker

KW - Bone metastases

KW - Castration-resistant prostate cancer

KW - Mechanism of action

KW - Prognostic marker

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85054423198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054423198&partnerID=8YFLogxK

U2 - 10.2217/fon-2018-0087

DO - 10.2217/fon-2018-0087

M3 - Review article

C2 - 29925281

AN - SCOPUS:85054423198

SN - 1479-6694

VL - 14

SP - 2543

EP - 2556

JO - Future Oncology

JF - Future Oncology

IS - 24

ER -

Alkaline phosphatase in metastatic castration-resistant prostate cancer: Reassessment of an older biomarker

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this